The characterization of the IL-6/GMDS-AS1/HuR/STAT3 axis provides a new perspective for understanding the pathogenesis of colitis-associated CRC and a novel diagnostic and therapeutic target in CRC. This evidence concerns the gene STAT3 and colorectal carcinoma.